Sildenafil Tablet
Product Images NDC 53746-351

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 53746-351). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Of New York Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4 (Sildenafil Tablets 1)

Chemical structure of Sildenafil, showing its molecular components including nitrogen, oxygen, carbon, hydrogen atoms arranged in a complex heterocyclic system with a sulfonyl group, piperazine ring, and carboxylic acid groups.*

FDA Label Image

1 (Sildenafil Tablets 2)

A horizontal dot plot chart displaying fold change and 90% confidence intervals for pharmacokinetic parameters AUC and Cmax of interacting drugs relative to Sildenafil alone. The chart categorizes interacting drugs such as Atorvastatin, Azithromycin, Bosentan, and others, and provides dosage recommendations including 'No dose adjustment' and 'Coadministration not recommended.' The horizontal axis represents change relative to Sildenafil alone with a vertical solid line at 1.*

FDA Label Image

1 (Sildenafil Tablets 3)

A forest plot showing fold changes and 90% confidence intervals for various interacting drugs relative to the interacting drug alone. The chart lists drugs including Acenocoumarol, Aspirin, Atorvastatin, Bosentan, Doxazosin (three dosages), Ethinyloestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide, with corresponding recommendations on dose adjustment. The horizontal axis measures change relative to the interacting drug, ranging from 0.5 to 2, with a vertical solid line at 1 indicating no change.*

FDA Label Image

F7c6df1a-figure-05 (Sildenafil Tablets 4)

A line chart showing change from baseline (in meters) over weeks 4, 8, and 12 with multiple data series labeled Sildenafil 40mg TID, Placebo, Sildenafil 60mg TID, and Sildenafil 20mg TID. The x-axis is labeled Week of Study and the y-axis is Change from Baseline (meters). Error bars indicate variability for each data point.*

FDA Label Image

10.1 (Sildenafil Tablets 5)

A forest plot illustrating placebo-corrected changes in 6-minute walk distance (meters) for Sildenafil 20 mg taken three times daily (TID) across various subgroups, including baseline walk distance, PAH etiology, functional class, gender, age, mean pulmonary arterial pressure, and pulmonary vascular resistance index. Data points show comparison between placebo and Sildenafil groups with confidence intervals.*

FDA Label Image

F7c6df1a-figure-07 (Sildenafil Tablets 6)

A survival-type line graph comparing the percentage of subjects without a clinically worsening event over time between Sildenafil and placebo groups. The x-axis represents days from randomization (0 to 112 days), and the y-axis shows the percentage without events (0% to 100%). The Sildenafil group maintains a higher percentage without worsening events compared to placebo.*

FDA Label Image

Label (Sildenafil Tablets 7)

Label for Sildenafil Tablets USP 20 mg oral tablets, containing 90 tablets per package. The label includes NDC 53746-351, manufacturer Amneal Pharmaceuticals of New York LLC, and storage instructions. The label features a sample tablet image marked with 'AN 351' and states 'Rx only.' A QR code and barcode are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.